Literature DB >> 25031886

The biochemical prognostic factors of subclinical hypothyroidism.

You Jin Lee1.   

Abstract

Entities:  

Year:  2014        PMID: 25031886      PMCID: PMC4091485          DOI: 10.3803/EnM.2014.29.2.144

Source DB:  PubMed          Journal:  Endocrinol Metab (Seoul)        ISSN: 2093-596X


× No keyword cloud information.
Subclinical hypothyroidism (SCH) is a very common condition and is defined as elevated serum thyroid-stimulating hormone (TSH) level with normal levels of circulating free thyroxine and triiodothyronine [1]. Recent population-based Korean studies have reported a high prevalence of 11% to 17% [2]. SCH is more common in women (6% to 10%) than in men (2% to 4%) [3,4,5]. Age is also a well-known risk factor. Some large studies showed significant positive correlation between age and SCH prevalence [6]. Serum thyroid peroxidase antibody (TPO Ab) positivity is associated with the prevalence of SCH [3,4,7]. In the Whickham 20-year follow-up study, risk of developing overt hypothyroidism was significantly higher in subjects with positive TPO Ab and increased TSH level than in those with only elevated TSH level [8]. In addition, iodine intake [9], racial differences [4], cigarette smoking [10], and cold environmental temperature [11] have also been suggested as risk factors of SCH. There have been some controversies about effects of SCH on obesity, dyslipidemia, cardiovascular disease, and cognition [12,13,14,15,16,17]. Some studies showed increased total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels in SCH subjects [6], while other studies showed no differences in lipid profile between SCH and euthyroid subjects [4]. A randomized double-blind placebo-controlled trial, 12-month levothyroxine treatment with 31 patients resulted in significant reductions in TC and LDL-C levels compared with those of 32 placebo subjects [17]. Therefore, the treatment of SCH is controversial. Prediction of progression of overt hypothyroidism is very important in a clinical setting. However, there are no definite predicting factors. In the study of Lee et al. [18], the authors compared characteristics of SCH patients according to initial TSH level and spontaneous improvement and identified predicting factors of progression to overt hypothyroidism. Higher initial TSH level and TPO-Ab positivity or titers were significantly correlated with maintenance of SCH and unfavorable lipid profiles. Initial TSH level was an independent and strong prognostic factor even in SCH subjects with mildly elevated TSH (5 to 10 mU/L). Although more studies are needed, initial TSH level and TPO Ab titer are very useful predicting factors when deciding on treatment for SCH.
  17 in total

1.  Subclinical thyroid dysfunction as a risk factor for cardiovascular disease.

Authors:  John P Walsh; Alexandra P Bremner; Max K Bulsara; Peter O'Leary; Peter J Leedman; Peter Feddema; Valdo Michelangeli
Journal:  Arch Intern Med       Date:  2005-11-28

2.  Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study.

Authors:  A E Hak; H A Pols; T J Visser; H A Drexhage; A Hofman; J C Witteman
Journal:  Ann Intern Med       Date:  2000-02-15       Impact factor: 25.391

3.  Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study.

Authors:  A Iqbal; R Jorde; Y Figenschau
Journal:  J Intern Med       Date:  2006-07       Impact factor: 8.989

4.  Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom.

Authors:  J V Parle; J A Franklyn; K W Cross; S C Jones; M C Sheppard
Journal:  Clin Endocrinol (Oxf)       Date:  1991-01       Impact factor: 3.478

5.  The Colorado thyroid disease prevalence study.

Authors:  G J Canaris; N R Manowitz; G Mayor; E C Ridgway
Journal:  Arch Intern Med       Date:  2000-02-28

6.  Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population.

Authors:  Nils Knudsen; Peter Laurberg; Lone B Rasmussen; Inge Bülow; Hans Perrild; Lars Ovesen; Torben Jørgensen
Journal:  J Clin Endocrinol Metab       Date:  2005-05-03       Impact factor: 5.958

7.  Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).

Authors:  Joseph G Hollowell; Norman W Staehling; W Dana Flanders; W Harry Hannon; Elaine W Gunter; Carole A Spencer; Lewis E Braverman
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

8.  TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study).

Authors:  C Meier; J J Staub; C B Roth; M Guglielmetti; M Kunz; A R Miserez; J Drewe; P Huber; R Herzog; B Müller
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

9.  Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association.

Authors:  Jeffrey R Garber; Rhoda H Cobin; Hossein Gharib; James V Hennessey; Irwin Klein; Jeffrey I Mechanick; Rachel Pessah-Pollack; Peter A Singer; Kenneth A Woeber
Journal:  Endocr Pract       Date:  2012 Nov-Dec       Impact factor: 3.443

10.  The biochemical prognostic factors of subclinical hypothyroidism.

Authors:  Myung Won Lee; Dong Yeob Shin; Kwang Joon Kim; Sena Hwang; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2014-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.